Quantcast

Latest Richter's transformation Stories

2014-12-08 20:20:32

Data Show 84% Progression-Free Survival Rate at One Year and Improvement in Quality of Life SAN FRANCISCO, Dec. 8, 2014 /PRNewswire/ -- Pharmacyclics, Inc.

2014-12-05 12:25:02

- Updated results from pilot Phase II trial of the BCL2 targeting DNAi® therapeutic reported at ASH 2014 - VANCOUVER, BC and PLYMOUTH, MI, Dec.

2014-05-31 08:21:22

Results from Phase III RESONATE(TM) Trial Published in an Online First Edition of the New England Journal of Medicine SUNNYVALE, Calif., May 31, 2014 /PRNewswire/ -- Pharmacyclics, Inc.

2014-05-31 08:21:05

- Data include results from two Phase I studies of ABT-199/GDC-0199 in relapsed/refractory chronic lymphocytic leukemia (CLL) and various subtypes of non-Hodgkin's lymphoma (NHL) NORTH

2014-05-31 08:20:48

Oral presentation (Abstract 7014) and poster session (Abstract 7009) featured at the 50th annual meeting of the American Society of Clinical Oncology RARITAN, N.J., May 31, 2014 /PRNewswire/

2014-05-28 23:16:46

TG02 also shown to be equally active in CLL cells from patients prior to and following twelve months of ibrutinib therapy. San Diego (PRWEB) May 28, 2014

2013-06-20 23:30:02

Two clinical studies published in the New England Journal of Medicine with an accompanying editorial suggest that the novel agent ibrutinib shows real potential as a safe, effective, targeted treatment for adults with chronic lymphocytic leukemia (CLL) and for patients with mantle cell lymphoma (MCL).

2013-05-14 13:18:59

Doctors at Dartmouth-Hitchcock's Norris Cotton Cancer Center (NCCC) have found a combination of drugs to potentially treat chronic lymphocytic leukemia (CLL) more effectively.


Word of the Day
dynamitard
  • A political dynamiter.
The word 'dynamitard' is related to 'dynamite', which comes from a Greek root meaning 'power' and was coined by Alfred Nobel.